Sodium enoxaparin treatment of sensorineural hearing loss: an immune-mediated response?
The authors propose the existence of a new entity of autoimmune sensorineural hearing loss on the basis of diagnostic study and treatment experience with a series of 30 patients. Immunological mechanisms play an important role in the pathogenesis and natural course of various inner-ear diseases. Patients may present clinically with symptoms resembling Ménière's disease or even with sudden deafness. Currently, no widely used standard protocol for treatment of this autoimmune sensorineural hearing loss exists. Prompted by such observations, we implemented a protocol using a particular kind of heparin--sodium enoxaparin--with a low molecular weight. Patients were randomly assigned to two groups; to those in the first group, enoxaparin was administered subcutaneously at a dose of 2,000 IU twice daily for 10 days; the patients in the second group were treated with placebo. At the beginning and at the end of the therapy period, the patients were evaluated by instrumental examinations. Specifically excluded were patients with abnormal known coagulation. On discharge, all patients treated with enoxaparin presented both a subjective and objective decrease in symptoms. No patient experienced side effects from this treatment. The results indicate that administration of sodium enoxaparin abates sensorineural hearing loss in patients with autoimmune diseases. The clinical response to therapy can confirm diagnosis.
Mora
Renzo
R
ENT Department, University of Genoa, Italy. renzomora@libero.it
Jankowska
Barbara
B
Passali
Giulio Cesare
GC
Mora
Francesco
F
Passali
Francesco Maria
FM
Crippa
Barbara
B
Quaranta
Nicola
N
Barbieri
Marco
M
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D002097:C-Reactive Protein / Q000032:analysis; D017984:Enoxaparin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000925:Anticoagulants; D017984:Enoxaparin; D007136:Immunoglobulins; D002097:C-Reactive Protein